|
99741 |
Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
Enthalten in Case reports in nephrology and dialysis Bd. 12, 2022, Nr. 3: 238-247. 10 S.
|
|
|
|
99742 |
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 238-250. 13 S.
|
|
|
|
99743 |
Keratoprothesen: letzte Hoffnung bei schwersten Hornhauterkrankungen
Enthalten in Augenheilkunde up2date Bd. 12, 2022, Nr. 03: 229-245
|
|
|
|
99744 |
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 229-237. 9 S.
|
|
|
|
99745 |
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 209-217. 9 S.
|
|
|
|
99746 |
An Unusual Presentation of Rhabdomyolysis and Acute Kidney Injury after Physical Activity: A Case Report
Enthalten in Case reports in nephrology and dialysis Bd. 12, 2022, Nr. 3: 193-200. 8 S.
|
|
|
|
99747 |
Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie e.V
Enthalten in Transfusionsmedizin Bd. 12, 2022, Nr. 03: 190-190
|
|
|
|
99748 |
Die Verordnung (EU) 2017/746 des Europäischen Parlaments über In-vitro-Diagnostika
Enthalten in Transfusionsmedizin Bd. 12, 2022, Nr. 03: 184-189
|
|
|
|
99749 |
MRT bei Patienten mit LADI-Asymmetrie nicht zwingend erforderlich
Enthalten in Neuroradiologie Scan Bd. 12, 2022, Nr. 03: 183-184
|
|
|
|
99750 |
Messung der Hämodynamik zerebraler AVMs mittels Phasenkontrast-MRT
Enthalten in Neuroradiologie Scan Bd. 12, 2022, Nr. 03: 173-174
|
|
Administration
